Direct Oral Anticoagulants in Patients With Active Cancer

[1]  A. Torbicki,et al.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.

[2]  C. Indolfi,et al.  Standard Versus Ultrasound-Guided Cannulation of the Femoral Artery in Patients Undergoing Invasive Procedures: A Meta-Analysis of Randomized Controlled Trials , 2020, Journal of clinical medicine.

[3]  Y. Lacasse,et al.  DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis , 2020, Journal of Thrombosis and Thrombolysis.

[4]  C. Flowers,et al.  Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Loprinzi,et al.  Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial , 2020, Journal of thrombosis and haemostasis : JTH.

[6]  G. Meyer,et al.  The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. , 2019, European heart journal.

[7]  Agnes Y. Y. Lee,et al.  Direct Oral Anticoagulants in Cancer Patients , 2019, Seminars in Thrombosis and Hemostasis.

[8]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism , 2019, Journal of Vascular Surgery: Venous and Lymphatic Disorders.

[9]  G. Lyman,et al.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Indolfi,et al.  Percutaneous Closure Versus Medical Treatment in Stroke Patients With Patent Foramen Ovale , 2018, Annals of Internal Medicine.

[11]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism , 2017, The New England journal of medicine.

[12]  D. Rockey,et al.  Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. , 2017, The American journal of medicine.

[13]  A. Curcio,et al.  Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study , 2017, Front. Cardiovasc. Med..

[14]  C. Loprinzi,et al.  Apixaban and dalteparin in active malignancy associated venous thromboembolism , 2017, Thrombosis and Haemostasis.

[15]  C. Indolfi,et al.  Long-term outcomes of coronary artery bypass grafting versus stent-PCI for unprotected left main disease: a meta-analysis , 2017, BMC Cardiovascular Disorders.

[16]  J. Douketis,et al.  International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. , 2016, The Lancet. Oncology.

[17]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[18]  Jeroen J. Bax,et al.  ESC Guidelines on the diagnosis and management of acute pulmonary embolism , 2014 .

[19]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[20]  G. Raskob,et al.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies , 2013, Thrombosis Journal.

[21]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[22]  P. Prandoni,et al.  Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry , 2008, Haematologica.

[23]  S. Frostick,et al.  Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.

[24]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[25]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.